-
2025-523428-39-00
4
Mantle Cell Lymphoma
-
2025-523448-10-00
4
Gvhd Resistant to ruxolitinib and steroids
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523869-22-00
5
advanced or metastatic extrapulmonary neuroendocrine carcinoma
-
2025-524077-16-00
4
metastatic urothelial carcinoma
-
2025-521976-80-00
4
2026-05-28
Relapsed or Refractory
Multiple Myeloma (RRMM)
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-524001-33-00
4
2026-05-22
Graves’ Disease
-
2025-524265-24-00
5
2026-05-21
Dyslipidemia at High to Very High Cardiovascular Risk
-
2025-521074-34-00
4
2026-05-15
Allogeneic peripheral hematopoietic stem cell transplant
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-522896-27-00
4
2026-05-11
Asthma
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2025-521792-31-01
5
2026-04-07
Homozygous Familial Hypercholesterolemia (HoFH)
-
2025-521521-33-00
10
2026-04-02
Kidney transplant rejection
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-523037-25-00
4
2026-03-10
Patients at high risk for Cardiac Surgery Associated – Acute Kidney In
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-519706-13-00
6
2026-01-26
Patients with Stable or Unstable coronary syndromes who have undergone
-
2025-521352-38-00
5
2026-01-16
Hereditary Angioedema
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy